Research only
All of
ALZ.ORG Research Center Alzheimer's Association International Conference ISTAART Journal Grants TrialMatch Press Donate Contact

Corporate Symposia - non-CME

Monday, July 25
The Fairmont – Canadian Ballroom
6:30 – 9 p.m.
Redefining When Alzheimer’s Disease Begins: Implications for Future Treatments

Leading experts will explore historical perspectives of AD and evolution of its diagnosis: latest thinking in diagnosis and treatment; preclinical criteria; next steps to early intervention; learnings from genetically defined populations; what can be understood from sporadic AD. Recent changes in diagnostic paradigm; biomarkers; innovative trial platforms, ethics.

Sponsored by: Janssen Research & Development LLC.



Monday, July 25
The Westin Harbour Castle Hotel – Frontenac Ballroom
6:30 – 8 p.m.
Transforming Clinical Trials in Alzheimer’s Disease: Innovations and Partnerships

Alzheimer’s disease (AD) clinical trials need major updates. An international expert panel will explore the current issues and highlight key approaches that are transforming AD trials: fast-start networks and trial-ready cohorts to accelerate recruitment, biomarker tools to aid patient identification and community partnerships across clinical, research and patient groups.

Sponsored by: F. Hoffmann-La Roche Ltd.



Monday, July 25
InterContinental Hotel – Ballroom
7 – 8:45 p.m.
Emerging Trends in Alzheimer’s Disease, the Rationale for Combination Treatments

With the increasing challenge in finding new and more effective treatments for Alzheimer’s disease, optimization of available and developing treatments becomes ever more important. This symposium covers the emerging trends in Alzheimer’s drug development with a specific focus on the scientific rationale for combination of current and future treatments.

Sponsored by: H. Lundbeck A/S & Otsuka Pharmaceutical Co. Ltd.



Tuesday, July 26
The Westin Harbour Castle Hotel – Frontenac Ballroom
6 – 9 p.m.
The Metabolic Hypothesis of AD: Past, Present and Future

The symposium will highlight the latest research on the metabolic hypothesis of Alzheimer’s disease (AD). Speakers will present the need for innovative and alternative approaches to AD drug development and how the metabolic hypothesis of AD is providing exciting new potential therapies, several with near term clinical data readout.

Sponsored by: Accera®

RSVP for Accera Symposium Dinner



Tuesday, July 26
The Fairmont Royal York Hotel – Canadian Ballroom
6 – 9 p.m.
Neuropsychiatric Symptoms and Alzheimer’s Disease: Current and Future Perspectives

Join the experts and your peers for dinner and discussion about neuropsychiatric symptoms of Alzheimer’s disease and the current challenges in patient assessment and diagnosis. The distinguished faculty will outline the need for standardized assessment tools and outcomes measures, review current treatment options and highlight unmet clinical and patient needs.

Sponsored by: Avanir® Pharmaceuticals



Wednesday, July 27
The Fairmont Royal York Hotel – Canadian Ballroom
6 – 8:30 p.m.
The Debate Continues: Unraveling the Science of Alzheimer’s Disease

To unravel the science of Alzheimer’s disease, a group of esteemed faculty will question timely topics—disease pathways, mechanisms and treatment goals—while providing supporting data within the context of an exciting, engaging debate. This signature event will close with a thought-provoking keynote discussion. Space is limited, please pre-register.

Sponsored by: Axovant





back to top
Where the world reveals the latest dementia research • Register now